Prominent Investment Bank Maintains Buy Rating on Bioscience Company
Anixa Biosciences: Current Developments and Future Prospects.
On Monday, H.C. Wainwright & Co. adjusted its outlook on Anixa Biosciences (NASDAQ: ANIX) shares, reducing the 12-month price target to $7.00 from the previous $12.00 while maintaining a Buy rating. This adjustment is based on a recent financial report and a new partnership focused on cancer vaccine development. $Anixa Biosciences(ANIX.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
